Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan;76(1):22-31.
doi: 10.1111/pcn.13304. Epub 2021 Nov 17.

Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study

Jun Ishigooka  1 , Kazuyuki Nakagome  2 , Tetsuro Ohmori  3 , Nakao Iwata  4 , Ken Inada  1 , Jun-Ichi Iga  2 , Taro Kishi  4 , Kiyoshi Fujita  5 , Yuka Kikuchi  6 , Toshiaki Shichijo  7 , Hideaki Tabuse  8 , Shotatsu Koretsune  9 , Hiroshi Terada  10 , Haruko Terada  10 , Toshifumi Kishimoto  11 , Yuichiro Tsutsumi  12 , Yoshiki Kanda  13 , Kazutaka Ohi  14 , Kanji Sekiyama  15
Affiliations
Randomized Controlled Trial

Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study

Jun Ishigooka et al. Psychiatry Clin Neurosci. 2022 Jan.

Abstract

Aim: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone).

Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 52-week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality-of-life scores [Personal and Social Performance Scale (PSP) and EuroQol-5 dimensions], and safety.

Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin.

Conclusion: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.

Keywords: discontinuation rate; long-term effectiveness; remission rate; second generation antipsychotics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition (CONSORT flow chart). ITT, intent to treat; PPS, per protocol set; SP, safety population.
Fig. 2
Fig. 2
Rates of treatment discontinuation (primary endpoint) from the time of randomization. Log‐rank test: P = 0.9771.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Charlson FJ, Ferrari AJ, Santomauro DF et al. Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr. Bull. 2018; 44: 1195–1203. - PMC - PubMed
    1. The Ministry of Health, Labour and Welfare. Statistics by Ministry of Health, Labour and Welfare, as of 2008. [Cited 3 November 2020] Available from URL: http://www.mhlw.go.jp/kokoro/speciality/detail_into.html.
    1. National Institute for Health and Care Excellence. NICE guideline 2014. Psychosis and schizophrenia in adults: prevention and management. [Cited 3 November 2020] Available from URL: https://www.nice.org.uk/guidance/cg178/chapter/1‐Recommendations#promoti.... - PubMed
    1. American Psychiatric Association . APA practical guideline 2019. [Cited 3 November 2020] Available from URL: https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.177901. https://www.psychiatry.org/psychiatrists/practice/clinical‐practice‐guid... - DOI
    1. The Japanese Society of Neuropsychopharmacology. “Guideline for Pharmacological Therapy of Schizophrenia” [Cited 3 November 2020] Available from URL: http://www.asas.or.jp/jsnp/csrinfo/03.html. - PMC - PubMed

Publication types